CNCR vs. XBI

Last updated Jun 25, 2026

CNCR (Loncar Cancer Immunotherapy ETF) and XBI (SPDR S&P Biotech ETF) are both Health & Biotech Equities funds - CNCR tracks the Loncar Cancer Immunotherapy Index while XBI tracks the S&P Biotechnology Select Industry Index. Both are passively managed. CNCR charges 0.79%/yr vs 0.35%/yr for XBI.

Performance

CNCR vs. XBI - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Loncar Cancer Immunotherapy ETF (CNCR) and SPDR S&P Biotech ETF (XBI). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

CNCR

• 1D: 0.00%
• 1M: 0.00%
• YTD: —
• 6M: —
• 1Y: —
• 3Y*: —
• 5Y*: —
• 10Y*: —

XBI

• 1D: 1.82%
• 1M: 13.82%
• YTD: 22.90%
• 6M: 18.65%
• 1Y: 79.43%
• 3Y*: 20.96%
• 5Y*: 1.67%
• 10Y*: 11.35%

*Multi-year figures are annualized to reflect compound growth (CAGR)

CNCR vs. XBI - Yearly Performance Comparison

	2026 (YTD)
CNCR Loncar Cancer Immunotherapy ETF	0.00%
XBI SPDR S&P Biotech ETF	24.14%

CNCR vs. XBI - Sectors Allocation Comparison

Sectors	CNCR	XBI
Healthcare	96.6%	99.7%
Financial Services	3.3%	0.3%
Basic Materials	-	0.2%
Communication Services	-	-
Consumer Cyclical	-	-
Consumer Defensive	-	-
Energy	-	-
Industrials	-	-
Real Estate	-	-
Technology	-	-
Utilities	-	-

Return for Risk

CNCR vs. XBI — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

CNCR

Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.

XBI

XBI Risk / Return Rank: 92
XBI Sharpe Ratio Rank: 93
XBI Sortino Ratio Rank: 92
XBI Omega Ratio Rank: 86
XBI Calmar Ratio Rank: 96
XBI Martin Ratio Rank: 94

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

CNCR vs. XBI - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Loncar Cancer Immunotherapy ETF (CNCR) and SPDR S&P Biotech ETF (XBI). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.

	CNCR	XBI	Difference
Sharpe ratio: Return per unit of total volatility	—	3.02	—
Sortino ratio: Return per unit of downside risk	—	3.88	—
Omega ratio: Gain probability vs. loss probability	—	1.47	—
Calmar ratio: Return relative to maximum drawdown	—	8.21	—
Martin ratio: Return relative to average drawdown	—	24.27	—

Drawdowns

CNCR vs. XBI - Drawdown Comparison

The maximum CNCR drawdown since its inception was 0.00%, smaller than the maximum XBI drawdown of -63.89%. Use the drawdown chart below to compare losses from any high point for CNCR and XBI.

Drawdown Indicators

	CNCR	XBI	Difference
Max Drawdown Largest peak-to-trough decline	0.00%	-63.89%	+63.89%
Max Drawdown (1Y) Largest decline over 1 year	—	-9.72%	—
Max Drawdown (3Y) Largest decline over 3 years	—	-32.99%	—
Max Drawdown (5Y) Largest decline over 5 years	—	-54.71%	—
Max Drawdown (10Y) Largest decline over 10 years	—	-63.89%	—
Current Drawdown Current decline from peak	0.00%	-13.39%	+13.39%
Average Drawdown Average peak-to-trough decline	0.00%	-20.93%	+20.93%
Ulcer Index Depth and duration of drawdowns from previous peaks	—	3.28%	—

Volatility

Volatility by Period

	CNCR	XBI	Difference
Volatility (1M) Calculated over the trailing 1-month period	—	9.94%	—
Volatility (6M) Calculated over the trailing 6-month period	—	21.21%	—
Volatility (1Y) Calculated over the trailing 1-year period	0.00%	26.52%	-26.52%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	0.00%	32.29%	-32.29%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	0.00%	32.00%	-32.00%

CNCR vs. XBI - Expense Ratio Comparison

CNCR has a 0.79% expense ratio, which is higher than XBI's 0.35% expense ratio.

Dividends

CNCR vs. XBI - Dividend Comparison

CNCR has not paid dividends to shareholders, while XBI's dividend yield for the trailing twelve months is around 0.38%.

Position	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
CNCR Loncar Cancer Immunotherapy ETF	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
XBI SPDR S&P Biotech ETF	0.38%	0.37%	0.15%	0.02%	0.00%	0.04%	0.20%	0.00%	0.28%	0.24%	0.26%	0.61%

Frequently Asked Questions

Which ETF is better, CNCR or XBI?

On fees, XBI is cheaper at 0.35% per year. The better choice depends on whether you care most about return, fees, risk, or income.

Which ETF is cheaper, CNCR or XBI?

XBI is cheaper with a 0.35% expense ratio, compared with 0.79% for CNCR.

Which ETF pays a higher dividend yield, CNCR or XBI?

XBI has the higher dividend yield at 0.38%, compared with 0.00% for CNCR.

What is the main difference between CNCR and XBI?

CNCR tracks Loncar Cancer Immunotherapy Index, while XBI tracks S&P Biotechnology Select Industry Index. They also come from different issuers: Exchange Traded Concepts and State Street. Their fees differ too: 0.79% for CNCR and 0.35% for XBI.